ADMA Biologics vs Vericel
ADMA and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADMA and VCEL compare
ADMA Biologics and Vericel are about the same size, with market caps of $3.0B and $3.0B.
On earnings, ADMA Biologics is cheaper: it trades at 17.1× trailing earnings, against 101× for Vericel.
Vericel grew revenue faster over the last twelve months (25.3% versus 6.3% for ADMA Biologics).
ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 35.1% compared with 10.3% at Vericel.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADMA | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $3.0B |
| Share price | $13.19 | $59.45 |
| Change, 1 year | −10.3% | 52.5% |
| Change, 5 years | 762% | 34.1% |
| Beta (5Y) | 0.64 | 1.04 |
| Employees | 647 | 398 |
| StockData Score | ||
| Total score | 16 | 16 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 5 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.1× (better) | 101× |
| P/S | 5.7× (better) | 9.4× |
| P/B | 6.7× (better) | 7.9× |
| EV/EBITDA | 12.2× (better) | 70.8× |
| P/FCF | 22.2× (better) | 52.6× |
| FCF yield | 4.5% (better) | 1.9% |
| Fair value | $21.21 | $16.78 |
| Margin of safety | 37.8% (better) | −254% |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 25.3% (better) |
| Revenue growth, 5Y average | 64.6% (better) | 17.3% |
| Net income growth (TTM) | −12.9% | 155% (better) |
| EPS growth (TTM) | −9.4% | 211% (better) |
| EPS growth, 5Y average | – | 39.8% |
| Profitability | ||
| Gross margin | 68.5% | 74.5% (better) |
| Operating margin | 46.5% (better) | 8.3% |
| Net margin | 35.1% (better) | 10.3% |
| FCF margin | 25.6% (better) | 17.9% |
| Return on equity | 41.9% (better) | 9.4% |
| Return on invested capital | 39.4% (better) | 10.6% |
| Financial health | ||
| Debt / equity | 0.45 (better) | 0.00 |
| Net debt / EBITDA | 0.29 | – |
| Interest coverage | 22.8× | 42.0× (better) |
| Current ratio | 6.04 (better) | 5.13 |
| Altman Z-score | 8.56 | 14.07 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 6.4% (better) | −0.25% |
| Shareholder yield | 6.4% (better) | −0.25% |
| Ownership | ||
| Held by institutions | 91.8% | 108% |
| Held by insiders | 3.0% | 1.3% |
| Insider net buying, 12 months | −$2.5M (better) | −$11.0M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 8.3% | 10.6% |
Go deeper
- ADMA stock overview
- ADMA income statement
- ADMA valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.